KemPharm (KMPH) to Release Quarterly Earnings on Thursday

KemPharm (NASDAQ:KMPHGet Rating) will be announcing its earnings results after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.

KemPharm (NASDAQ:KMPHGet Rating) last posted its earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). KemPharm had a positive return on equity of 7.03% and a negative net margin of 29.86%. On average, analysts expect KemPharm to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of KemPharm stock opened at $4.54 on Thursday. The stock’s 50-day moving average is $4.99 and its 200-day moving average is $6.94. KemPharm has a one year low of $4.10 and a one year high of $15.70.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada increased its position in KemPharm by 22.1% during the third quarter. Royal Bank of Canada now owns 9,313 shares of the specialty pharmaceutical company’s stock worth $86,000 after buying an additional 1,687 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of KemPharm by 72.0% in the second quarter. Wells Fargo & Company MN now owns 5,719 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,394 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of KemPharm by 21.3% in the fourth quarter. The Manufacturers Life Insurance Company now owns 17,764 shares of the specialty pharmaceutical company’s stock valued at $155,000 after purchasing an additional 3,122 shares during the last quarter. Invesco Ltd. grew its position in shares of KemPharm by 29.2% in the third quarter. Invesco Ltd. now owns 14,644 shares of the specialty pharmaceutical company’s stock valued at $136,000 after purchasing an additional 3,314 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in shares of KemPharm by 31.1% in the third quarter. Cubist Systematic Strategies LLC now owns 14,946 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 3,543 shares during the last quarter. 32.39% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently issued reports on KMPH shares. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a report on Thursday. StockNews.com assumed coverage on KemPharm in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, HC Wainwright raised KemPharm from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $10.00 to $11.00 in a research report on Monday, January 31st.

KemPharm Company Profile (Get Rating)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Recommended Stories

Earnings History for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.